Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients
Mira Keyes(BC Cancer Agency), William Morris(Vanderbilt University), Vincent Lapointe, Ingrid Spadinger, Tom Pickles, Howard Pai(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), Stacy Miller, Alexander Agranovich, Ross Halperin(BC Cancer Agency), Veronika Moravan, Winkle Kwan, Mitchell Liu
International Journal of Radiation Oncology*Biology*Physics
December 27, 2008
Cited by 180
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319